The sixth vaccine to be authorised by the World Health Organisation (WHO) for its emergency listing, receiving WHO validation for safety, efficacy and quality. Developed by the Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG), Sinopharm is an inactivated vaccine called SARS-CoV-2 Vaccine.
OGL Medical Group has received approval under the SAR to provide Sinopharm COVID-19 vaccines in Singapore. Registration for interest in the Sinopharm vaccine is now available.
Thank you for your interest in the Sinopharm Covid-19 Vaccine.
The demand for the vaccine exceeds our available stock and we regret to inform you that our first batch of vaccines has been fully committed as of 31 August 2021.
OGL Medical Group is working hard to procure a steady supply of vaccines from our manufacturing partner and will be releasing details once we have confirmation on the delivery of the next batch.
Thank you for your patience and we look forward to updating you when we have further information. Please register your interest in the vaccine below for updates on the availability of the vaccine.
Individuals aged 18 years and older, with no history of anaphylaxis.
Individuals with a history of anaphylaxis or any form of severe allergic reactions to medication/food/vaccination should not be administered with the vaccine.Individuals with a body temperature over 38.5ºC should postpone vaccination until the fever subsides.
According to WHO, the recommendation is two-dose with an interval of 3-4 weeks between first and second dose.
SAGE (Strategic Advisory Group of Experts) from WHO has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.
The most commonly reported side effects in this trial were fever and pain at the injection site. Based on the data from clinical trials, the most common side effects recorded were:
We will send you a confirmation within 24 hours.